Venus Remedies Limited, the global pharmaceutical company received novel antibiotic product Potentox patented from Mexico. The patent was granted to it by the Mexican Institute of Industrial Property (IMPI). The patent will provide it protection of composition of Potentox.
The patent will facilitate the company with an exclusivity period for Potentox up to 2025. Potentox is also patented from other countries such as Ukraine, Canada, South Africa, South Korea, New Zealand, Australia, USA and India.
Potentox is the antibiotic adjuvant entity (AAE). It is the drug used for treatment of hospital-acquired pneumonia as well as febrile neutropenia infections which are caused by quinolones or aminoglycoside-resistant microbes. This drug is growing at the compound annual growth rate (CAGR) of 50 percent since 2010.
The overall international market for the treatment of hospital-acquired bacterial infections was found out to be 9 billion US dollar in 2010. Potentox is composed for addressal of demands of around 50 percent of this market.
DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.